Citation Impact
2 from Science/Nature 64 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
Works of М. В. Копп being referenced
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
2013
Author Peers
| Author | Oncology | PRM | Surgery | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| М. В. Копп | 186 | 98 | 56 | 98 | 16 | 351 | |
| N. S. Dellas | 24 | 15 | 650 | ||||
| Caetana M. Carvalho | 61 | 76 | 38 | 762 | 50 | 1.6k | |
| Zixin Chen | 19 | 111 | 39 | 237 | 18 | 429 | |
| Juan C. Ordóñez-Calderón | 11 | 415 | |||||
| Jarrod B. King | 69 | 30 | 19 | 478 | 44 | 1.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...